Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Antibiotic prophylaxis and its effect on postprocedural adverse events in endoscopic retrograde cholangiopancreatography for primary sclerosing cholangitis

Gustafsson, Arvid LU orcid ; Enochsson, Lars ; Tingstedt, Bobby LU and Olsson, Greger LU (2023) In JGH Open 7(1). p.24-29
Abstract

BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) is characterized by multiple strictures of the biliary tree. Patients with PSC frequently require repeated endoscopic retrograde cholangiopancreatography (ERCP) procedures. These procedures are encumbered by an increased incidence of infectious adverse events such as cholangitis. Evidence regarding whether antibiotic prophylaxis (AP) should be administered is sparse; however, prophylaxis is recommended. We aimed to determine whether AP affects the rate of postprocedural infectious and overall adverse events.

METHODS: We conducted a retrospective cohort study and extracted all ERCP procedures with indicated PSC performed between 1 January 2006 and 31 December 2019, which were... (More)

BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) is characterized by multiple strictures of the biliary tree. Patients with PSC frequently require repeated endoscopic retrograde cholangiopancreatography (ERCP) procedures. These procedures are encumbered by an increased incidence of infectious adverse events such as cholangitis. Evidence regarding whether antibiotic prophylaxis (AP) should be administered is sparse; however, prophylaxis is recommended. We aimed to determine whether AP affects the rate of postprocedural infectious and overall adverse events.

METHODS: We conducted a retrospective cohort study and extracted all ERCP procedures with indicated PSC performed between 1 January 2006 and 31 December 2019, which were registered in the Swedish Registry for Gallstone Surgery and ERCP (GallRiks). The exclusion criteria were incomplete 30-day follow-up, non-index procedures, or ongoing antibiotics. The main outcomes were postprocedural infectious adverse events and overall adverse events at the 30-day follow-up.

RESULTS: A total of 2144 procedures with indication of PSC were eligible for inclusion. AP was administered in 1407 (66%) of these procedures. Patients receiving AP were slightly younger (44 vs 46 years, P = 0.005) and had more comorbidities (ASA ≥3, 19.8% vs 13.6%; P  < 0.001). Procedures with AP demonstrated an infectious adverse event rate of 3.3% compared to 4.5% for non-AP procedures (P = 0.19). Postprocedural infectious adverse events (odds ratio [OR] 0.76, 95% confidence interval [CI] 0.48-1.21) and overall adverse events (OR 0.79, 95% CI 0.60-1.04) did not differ between AP and non-AP.

CONCLUSION: Patients with PSC who undergo ERCP have the same frequency of adverse events regardless of whether AP was used.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
JGH Open
volume
7
issue
1
pages
24 - 29
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85143908714
  • pmid:36660048
ISSN
2397-9070
DOI
10.1002/jgh3.12846
language
English
LU publication?
yes
additional info
© 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
id
39af1b28-1993-4884-a09e-4dcbad570b11
date added to LUP
2023-03-12 21:11:15
date last changed
2024-04-18 19:23:44
@article{39af1b28-1993-4884-a09e-4dcbad570b11,
  abstract     = {{<p>BACKGROUND AND AIM: Primary sclerosing cholangitis (PSC) is characterized by multiple strictures of the biliary tree. Patients with PSC frequently require repeated endoscopic retrograde cholangiopancreatography (ERCP) procedures. These procedures are encumbered by an increased incidence of infectious adverse events such as cholangitis. Evidence regarding whether antibiotic prophylaxis (AP) should be administered is sparse; however, prophylaxis is recommended. We aimed to determine whether AP affects the rate of postprocedural infectious and overall adverse events.</p><p>METHODS: We conducted a retrospective cohort study and extracted all ERCP procedures with indicated PSC performed between 1 January 2006 and 31 December 2019, which were registered in the Swedish Registry for Gallstone Surgery and ERCP (GallRiks). The exclusion criteria were incomplete 30-day follow-up, non-index procedures, or ongoing antibiotics. The main outcomes were postprocedural infectious adverse events and overall adverse events at the 30-day follow-up.</p><p>RESULTS: A total of 2144 procedures with indication of PSC were eligible for inclusion. AP was administered in 1407 (66%) of these procedures. Patients receiving AP were slightly younger (44 vs 46 years, P = 0.005) and had more comorbidities (ASA ≥3, 19.8% vs 13.6%; P  &lt; 0.001). Procedures with AP demonstrated an infectious adverse event rate of 3.3% compared to 4.5% for non-AP procedures (P = 0.19). Postprocedural infectious adverse events (odds ratio [OR] 0.76, 95% confidence interval [CI] 0.48-1.21) and overall adverse events (OR 0.79, 95% CI 0.60-1.04) did not differ between AP and non-AP.</p><p>CONCLUSION: Patients with PSC who undergo ERCP have the same frequency of adverse events regardless of whether AP was used.</p>}},
  author       = {{Gustafsson, Arvid and Enochsson, Lars and Tingstedt, Bobby and Olsson, Greger}},
  issn         = {{2397-9070}},
  language     = {{eng}},
  number       = {{1}},
  pages        = {{24--29}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{JGH Open}},
  title        = {{Antibiotic prophylaxis and its effect on postprocedural adverse events in endoscopic retrograde cholangiopancreatography for primary sclerosing cholangitis}},
  url          = {{http://dx.doi.org/10.1002/jgh3.12846}},
  doi          = {{10.1002/jgh3.12846}},
  volume       = {{7}},
  year         = {{2023}},
}